psalexa
logo

Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017

Retinitis Pigmentosa Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designations, Collaborations, and Other Developments

Published: November 2017
Report Code: LS11345
Available Format:
Pages: 121

Note: This report can also be updated as of date and delivered within 1-2 workings days of purchase confirmation

Overview

Retinitis pigmentosa is a group of rare genetic disorders, characterized by the breakdown and loss of cells in the retina of eye. Retinitis pigmentosa is familial, inherited in a variety of ways, including dominant, recessive, and sex-linked recessive. The symptoms of the disease include, loss of night vision, gradual loss of central and peripheral vision, and problems with color vision, difficulty in the daily activities such as reading, driving, walking, and reorganization of the faces and objects. Retinitis pigmentosa can be diagnosed by the electroretinogram (ERG), and visual field testing and genetic testing. Proretina Therapeutics, S.L. is in the process of developing PRO-001 and PRO-015 as a neuroprotective agent and gene therapy, respectively, for the treatment of retinitis pigmentosa.

 

RETINITIS PIGMENTOSA THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)

Retinitis Pigmentosa Therapeutics Pipeline Analysis

Pipeline Analysis

As of November 2017, the retinitis pigmentosa therapeutics pipeline comprises of 38 drug candidates in different stages of development.

Competitive Landscape

Some of the players developing drugs for the treatment of retinitis pigmentosa include jCyte, Inc., Dompe Farmaceutici SpA, ProRetina Therapeutics, S.L., and Recursion Pharmaceuticals Inc.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 2500
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 3250
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 7750

Pre-Purchase Enquiry